… results in pediatric hematologic malignancies. This review … the PI3K/AKT/mTOR signaling
pathway in pediatric hematologic malignancies, the agents that are used to target this pathway, …

… target in developing effective treatments for hematologic tumors [5]. This review discusses
the function of the PI3K/Akt/mTOR pathway and its role in hematologic malignancies. …

… for the PI3K/Akt pathway in hematologic malignancies. … Although genetic alterations such
as a PI3K mutation, loss of … in hematologic tumors, activation of the PI3K/Akt pathway and its …

… To further explore the dysregulations of this pathway in hematologic neoplasms, … PI3K/Akt/mTOR
signaling pathway genes in hematologic malignancies using the cBioportal for Cancer …

… of the contribution of individual PI3K isoforms to immune cell function and their … the PI3K
pathway. We also consider whether manipulating other proximal elements of the PI3K signaling …

… The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis
of lymphoma. Deeper understanding of the diversity and biological impact of this …

… independent pro-survival pathway, phosphoinositide-3 Kinase/Akt/mammalian (PI3K/Akt/…
4E-BP1 and p70S6 independently of the PI3K/Akt/mTOR pathway [2]. Indeed, the activation of …

… Duvelisib demonstrated in vivo pharmacologic activity through rapid and sustained
reductions in p-AKT, a downstream marker of PI3K signaling and reductions in Ki-67 expression, …

… (PI3K) signaling pathway is associated with chemoresistance and poor prognosis of many
cancers, including hematological malignancies (… In summary, the PI3K signaling is frequently …

… in hematologic malignancies. In 2014, the PI3Kδ inhibitor idelalisib was the first of four PI3K
… PI3K signaling regulates key cellular activities such as cell survival, proliferation, metabolism…